Feedback / Questions
IFx-2.0 - TuHURA Bio
https://www.prnewswire.com/news-releases/tuhura-biosciences-received-fda-orphan-drug-designation-for-ifx-2-0-for-the-treatment-of-stage-iib-to-stage-iv-cutaneous-melanoma-302675770.html
Feb 2, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next